The short version
Melanotan I is an early research name commonly associated with afamelanotide, also called NDP-alpha-MSH or [Nle4,D-Phe7]-alpha-MSH. It is a linear 13-residue analog of alpha-melanocyte-stimulating hormone designed to produce stronger and longer melanocortin activity than the native peptide.
The evidence is unusually developed for a peptide discussed in online research catalogs. Laboratory and animal studies established melanocortin-1-receptor-linked pigmentation biology; controlled human studies measured pigmentation and ultraviolet-response markers; and randomized trials in erythropoietic protoporphyria supported a specific FDA-approved afamelanotide product.
That approval is narrow and product-specific. Scenesse is an FDA-approved controlled-release afamelanotide implant used to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. A vial sold as Melanotan I, MT-I, or afamelanotide is not thereby Scenesse, FDA approved, clinically equivalent, or supported by the finished product's evidence package.
Identity: Melanotan I, afamelanotide, and NDP-alpha-MSH
FDA's substance-registration record identifies afamelanotide as Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 and lists molecular formula C78H111N21O19. The record includes Melanotan I, Melanotan-1, NDP-alpha-MSH, and [Nle4,D-Phe7]-alpha-MSH as synonyms or mappings.
Those names converge on a represented molecule, but name matching is only the beginning of identity review. The norleucine substitution at position 4, D-phenylalanine at position 7, acetylated N-terminus, and amidated C-terminus are part of the structure. A different stereoisomer, terminal form, sequence, or modification is not the same compound.
FDA also states that inclusion in its substance-registration system does not imply regulatory review or approval. The UNII QW68W3J66U helps standardize afamelanotide identity; it does not authenticate a supplier lot or turn a raw material into an approved drug product.
Melanotan I is not Melanotan II or bremelanotide
Afamelanotide is a linear 13-residue alpha-MSH analog. Melanotan II is a shorter cyclic melanocortin analog, and bremelanotide is a distinct cyclic peptide developed from that lineage. Shared ancestry and overlapping receptor biology do not make the three compounds interchangeable.
The regulatory records are also separate. Scenesse contains afamelanotide for a defined EPP indication, while Vyleesi contains bremelanotide for its own approved indication. Melanotan II has no FDA-approved drug product. Evidence, labeling, safety findings, and analytical expectations should follow the exact molecule and finished product being discussed.
A storefront label such as MT-1 is therefore insufficient when the sequence and modifications are absent. Evidence matching should begin at the molecular level, not with the similarity of a product name.
Cell and receptor evidence: MC1R signaling and melanogenesis
Alpha-MSH signaling at the melanocortin-1 receptor on melanocytes can increase cyclic-AMP-linked melanogenic signaling and favor eumelanin production. Afamelanotide preserves this receptor pathway while its substitutions increase potency and prolong activity compared with native alpha-MSH in experimental systems.
Early chromatophore and skin-bioassay work found [Nle4,D-Phe7]-alpha-MSH to be a potent, long-acting melanotropin across several vertebrate preparations. These experiments helped establish biological activity and informed later pigmentation research.
A receptor response or melanogenesis marker is not a patient outcome. Cell type, receptor genotype, ligand concentration, exposure time, assay design, and the exact test article all affect interpretation. Mechanistic plausibility cannot establish clinical effectiveness, long-term safety, or equivalence between a supplier sample and Scenesse.
Animal evidence: pigmentation findings are model-specific
A mouse study found that [Nle4,D-Phe7]-alpha-MSH and related analogs shifted follicular pigment production toward eumelanogenesis at substantially lower experimental concentrations than native alpha-MSH. Other vertebrate studies reported prolonged pigment-cell responses in both laboratory and whole-animal preparations.
These models are useful for comparing melanotropin potency, persistence, and pigment biology. They do not recreate erythropoietic protoporphyria, establish protection from human phototoxic pain, or characterize the safety of a finished implant.
Animal pigmentation should also not be compressed into a general cancer-prevention claim. Pigment production, acute ultraviolet injury, DNA damage, long-term carcinogenesis, and clinical phototoxicity are distinct endpoints.
Early human pigmentation studies established a pharmacologic signal
A 1991 randomized, placebo-controlled study of 28 healthy men reported measurable skin darkening after exposure to the NDP-alpha-MSH analog. Later small studies connected the visible change to increased eumelanin rather than a simple increase in all pigment types.
A controlled study in 77 participants examined MC1R variants and reported increased melanin density in treated participants, including people carrying several receptor variants. A separate randomized study completed by 65 fair-skinned volunteers reported increased pigmentation and reductions in selected acute ultraviolet-damage markers.
These studies support a human pigmentation effect under their protocols. They do not prove prevention of skin cancer, eliminate ultraviolet risk, establish unrestricted cosmetic use, or validate any current online product. Biomarkers such as sunburn cells and thymine dimers are informative experimental endpoints, not substitutes for long-term clinical outcomes.
EPP changes the clinical question
Erythropoietic protoporphyria is a rare inherited disorder in which protoporphyrin accumulation can produce severe pain after light exposure. The clinical question is therefore not whether afamelanotide can create a cosmetic tan; it is whether a characterized product can increase pain-free light exposure and reduce the burden of phototoxic reactions in people with EPP.
That distinction matters for evidence interpretation. Pigmentation is part of the proposed pharmacology, but the patient-important outcomes include time in light without pain, phototoxic reactions, daily functioning, and quality of life.
Two randomized EPP trials supported a modest, measurable benefit
A 2015 publication reported two multicenter, randomized, double-blind, placebo-controlled trials: 74 participants in a European study and 94 in a U.S. study. Both evaluated a controlled-release afamelanotide implant in people with EPP.
Pain-free direct-light exposure was longer with afamelanotide in both trials. The European study also reported fewer phototoxic reactions, and disease-specific quality-of-life measures improved. The absolute exposure-time results differed substantially between the two trials, which shows how geography, behavior, light conditions, recording methods, and study duration can shape this endpoint.
These were positive pivotal studies, not proof of unlimited benefit. EPP is rare, participant numbers were necessarily modest, light exposure is partly behavior-dependent, and the results apply to the studied implant, population, endpoints, and protocol.
Observational EPP studies add duration but less causal certainty
Longer-term cohorts have reported sustained treatment continuation, improved EPP-specific quality of life, and generally consistent safety observations in clinical practice. One early report followed 115 patients across two European porphyria centers, while later postauthorization cohorts expanded real-world follow-up.
Observational evidence can reveal persistence, clinical-practice patterns, and events that short trials may miss. Without random assignment, it is more vulnerable to selection, discontinuation, expectation, reporting, seasonal, and center effects. Quality-of-life improvement in a treated cohort should not be interpreted as if it came from a long-term randomized comparison.
Real-world findings strengthen product-specific context but still do not authenticate or validate unrelated research-market material.
Scenesse approval is specific to one product and indication
FDA approved Scenesse in October 2019 to increase pain-free light exposure in adult patients with a history of phototoxic reactions from EPP. FDA's current label identifies afamelanotide as the active ingredient in a sterile, bioresorbable controlled-release implant.
The label also describes postmarketing serious hypersensitivity reactions, including anaphylaxis, and warns that the pharmacologic increase in pigmentation can darken pre-existing nevi and ephelides. These are finished-product safety statements, not evidence that an online research vial has been manufactured, formulated, or characterized to the same standard.
FDA approval does not transfer through an ingredient name. A loose peptide, a vial, a compounded preparation, and Scenesse can share a stated active sequence while differing in formulation, release behavior, impurities, stability, sterility assurance, manufacturing controls, labeling, and evidence.
Vitiligo evidence is separate from the approved EPP indication
A randomized multicenter study enrolled 55 adults with nonsegmental vitiligo and compared narrowband ultraviolet-B phototherapy alone with phototherapy plus an afamelanotide implant. The combination group showed faster and greater repigmentation on selected measures, particularly among participants with darker Fitzpatrick skin phototypes.
The study tested a combination, not afamelanotide alone, and enrolled a selected population. It cannot separate every contribution of the implant from the phototherapy schedule or establish the same result across all skin types and vitiligo patterns.
ClinicalTrials.gov currently lists a separate phase 3 Scenesse-plus-phototherapy study, NCT06109649, as active but not recruiting. The record was last updated July 8, 2025 and displays no posted results. Registration and estimated completion dates are not evidence of success, and Scenesse is not FDA approved for vitiligo as of October 29, 2026.
What the human evidence does not establish
The evidence supports a human pigmentation effect and a product-specific EPP approval. It does not establish that any afamelanotide-labeled material is equivalent to Scenesse, that pigmentation prevents skin cancer, or that findings from EPP apply to cosmetic tanning, vitiligo monotherapy, or other conditions.
Approved-product evidence also cannot answer the long-term safety of uncharacterized materials, different formulations, or different exposure patterns. The relevant benefit-risk conclusion belongs to the approved product, indication, population, and labeling.
No cited clinical study authenticates a current supplier lot. A paper can identify the intended molecule and biological question; only lot-connected analytical and manufacturing evidence can address the material offered for research.
- Human pigmentation does not equal proven cancer prevention
- EPP trial results are condition- and product-specific
- The vitiligo trial tested a combination with phototherapy
- ClinicalTrials.gov registration is not a result or approval
- Scenesse approval does not transfer to research vials
- Published studies do not authenticate current supplier inventory
Scientific evidence and supplier documentation answer different questions
Receptor and cell studies ask whether a defined test article changes melanocortin signaling. Animal studies examine a controlled model. Human trials report outcomes for participants receiving a characterized study product. FDA approval evaluates a finished product for a defined use.
Supplier documentation addresses a different chain: what sample was tested, whether it matches the offered lot, which method was used, what was expected, what was observed, and which attributes remain untested. It cannot borrow identity, sterility, stability, safety, or efficacy from Scenesse.
Research use only is an intended-use restriction, not a quality grade. It does not mean FDA approved, pharmaceutical grade, sterile, endotoxin controlled, clinically equivalent, or independently authenticated.
Analytical questions for Melanotan I research material
Identity review should begin with the complete afamelanotide sequence and modifications: norleucine at position 4, D-phenylalanine at position 7, the acetylated N-terminus, and the C-terminal amide. Reports should state the expected mass and the salt or counterion form used for quantitative interpretation.
Mass spectrometry can support molecular mass, but an intact-mass match alone does not prove sequence position, every stereocenter, peptide quantity, or formulation. Chromatography can characterize detected components under its method, but an HPLC area percentage is not net peptide content and does not establish sterility, endotoxin, water, counterion amount, residual solvents, aggregation, stability, or release behavior.
A defensible evidence chain connects catalog name, full structure, sample identifier, lot, laboratory, method, date, expected result, observed result, and reviewer. Equivalence to Scenesse would require a far broader finished-product evidence package than a peptide identity result and purity percentage.
- Full 13-residue sequence and terminal modifications
- Norleucine-4 and D-phenylalanine-7 identity
- Expected mass and stated salt or counterion form
- Lot-matched mass and chromatographic records
- Peptide content separated from HPLC area purity
- Water, counterion, residual-solvent, aggregation, and stability evidence where claimed
- Separate microbiological evidence for sterility or endotoxin claims
- No Scenesse-equivalence claim from ingredient naming alone
Limitations and unresolved questions
Long-term approved-product surveillance remains important because pivotal randomized trials were modest in size and rare harms cannot be fully characterized before approval. Postmarketing hypersensitivity reports have already changed the current U.S. label.
The relationship among pigmentation, acute ultraviolet biomarkers, real-world light behavior, and long-term dermatologic outcomes remains more complex than a single photoprotection claim. Disease-specific benefit in EPP should not be generalized to healthy populations.
For research-market materials, public records often leave stereochemistry, terminal chemistry, peptide content, counterion quantity, impurities, aggregation, microbiological quality, and stability unresolved. Clinical literature cannot fill those lot-specific gaps.
FAQ: Is Melanotan I the same as afamelanotide?
Melanotan I is an early research name commonly mapped to afamelanotide, NDP-alpha-MSH, or [Nle4,D-Phe7]-alpha-MSH. The name still does not prove that a particular product has the correct sequence, stereochemistry, terminal modifications, quantity, or quality.
FAQ: Is every afamelanotide or MT-I product FDA approved?
No. FDA approval applies to the Scenesse finished implant for its labeled EPP indication. A supplier vial, raw peptide, compounded preparation, or differently formulated product does not inherit that approval because it uses the same ingredient name.
FAQ: Does afamelanotide evidence apply to Melanotan II?
No. Afamelanotide is a linear 13-residue analog, while Melanotan II is a shorter cyclic peptide with different receptor pharmacology and a different evidence and regulatory record.
FAQ: Does 99% HPLC purity prove equivalence to Scenesse?
No. HPLC area purity under one method does not establish full identity, stereochemistry, absolute peptide content, formulation, controlled release, sterility assurance, stability, manufacturing controls, or clinical equivalence to the FDA-approved product.
The defensible conclusion
Afamelanotide has a coherent evidence chain from melanocortin biology through controlled human studies to a narrow FDA approval. Animal and early human pigmentation findings established pharmacology, while randomized EPP trials supported increased pain-free light exposure with a specific controlled-release implant.
The same evidence demands careful boundaries. Melanotan I is not Melanotan II, EPP benefit is not a universal tanning or photoprotection claim, vitiligo research is not an approved indication, and a research vial is not Scenesse. Reliable due diligence keeps molecular identity, model evidence, human outcomes, finished-product approval, and lot-specific supplier documentation separate.
Sources and further reading
Primary and standards-based sources used to frame this educational overview:
- FDA SRS: afamelanotide substance record (UNII QW68W3J66U)
- FDA: current Scenesse prescribing information
- FDA: multidisciplinary review of Scenesse NDA 210797
- FDA: Scenesse orphan-drug designation and approval record
- PubMed: prolonged melanotropin activity in vertebrate models
- PubMed: mouse follicular melanogenesis study
- PubMed: randomized early human skin-pigmentation study
- PubMed: melanin response across MC1R variant alleles
- PubMed: pigmentation and acute ultraviolet-damage markers
- PubMed: randomized afamelanotide trials in EPP
- PubMed: long-term observational EPP study
- PubMed: randomized afamelanotide plus narrowband UV-B vitiligo study
- ClinicalTrials.gov: phase 3 afamelanotide and NB-UVB vitiligo study NCT06109649
- DailyMed: current Scenesse drug record
Explore related resources
Peptide Due Diligence Research Brief
Keep the evidence in view.
Receive concise briefings on analytical testing, documentation quality, supplier transparency, and new additions to the research library.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free field guide.